虛擬臨床試驗市場 - 按研究設計、類型、階段、適應症、產業分類 - 全球預測 2024 年 - 2032 年

Virtual Clinical Trials Market - By Study Design, Type, Phases, Indication, Industry - Global Forecast 2024 - 2032

出版日期: 2024年03月08日 | 出版商:

Global Market Insights Inc. | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

虛擬臨床試驗市場規模預計從 2024 年到 2032 年將以 7.1% 的複合年成長率資料。並降低了整體成本。為此，虛擬試驗變得越來越受歡迎，因為它們為參與者提供了更大的可及性和便利性，從而改善了患者的招募、保留和多樣性。

2023 年 10 月，Elligo Health Research 與 Avallano 合作推出了 myTrialsConnect，這是一個由人工智慧驅動的臨床試驗招募和參與平台，允許患者參與試驗並與醫療保健提供者網路建立聯繫。領先企業的類似創新將對產業成長產生正面影響。

此外，一些監管機構擴大支持虛擬試驗方法，以提供更清晰的指導和框架。虛擬試驗在促進即時資料分析和決策以提高臨床研究過程的效率和速度方面的重要性日益增加，這將促進行業的成長。

虛擬臨床試驗市場分為研究設計、類型、階段、適應症、產業和地區。

根據研究設計，從 2024 年到 2032 年，觀測領域的市場規模將以 6.7% 的成長率資料。。虛擬觀察研究為參與者提供了更大的便利，從而提高了招募率和保留率。即時收集現實世界資料的能力也增強了研究結果的有效性和可靠性。

就產業而言，預計到 2032 年，醫療器材公司的虛擬臨床試驗市場將以 7.2% 的複合年成長率成長。虛擬試驗減少了與傳統試驗相關的後勤負擔，確保更快、更具成本效益的研究。對虛擬試驗方法的監管支持將進一步促進該細分市場的成長。

從地區來看，從 2024 年到 2032 年，亞太地區虛擬臨床試驗產業將以 7.6% 的複合年成長率顯著資料。對分散試驗方法的需求不斷成長，正在提高參與者的可及性和多樣性。支持性監管框架和指南的推出正在鼓勵虛擬試驗方法的採用。最近，COVID-19 大流行的爆發也加速了整個亞太地區向虛擬試驗的轉變，以確保在面對面互動受到限制的情況下研究的連續性。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 11 章：公司簡介

Clinical Ink
CROPRIME Ltd
ICON, plc
IQVIA Inc.
Medable, Inc.
Medidata
Oracle Corporation
Parexel International (MA) Corporation
PRA Health Sciences
Signant Health

簡介目錄

Product Code: 8438

Virtual Clinical Trials Market size is projected to expand at 7.1% CAGR from 2024 to 2032. The advancements in digital health technologies and telemedicine are enabling remote data collection, monitoring, and patient engagement while reducing the need for physical site visits and lowering overall costs. To that end, virtual trials have grown largely popular as they offer greater accessibility and convenience for participants, leading to improved patient recruitment, retention, and diversity.

In October 2023, Elligo Health Research collaborated with Avallano to introduce myTrialsConnect, an AI-driven clinical trial recruitment and engagement platform, allowing patients to participate in trials and connect with healthcare providers network. Similar innovations by leading players will positively influence the industry growth.

Additionally, several regulatory agencies are increasingly supporting virtual trial approaches for providing clearer guidance and frameworks. The growing importance of virtual trials in facilitating real-time data analysis and decision-making for enhancing the efficiency and speed of clinical research processes will add to the industry growth.

The virtual clinical trials market is segregated into study design, type, phase, indication, industry, and region.

Based on study design, the market size from the observational segment will expand at 6.7% growth rate from 2024 to 2032. Rapid advancements in digital technologies is enabling remote collection of data, making it easier to conduct observational studies without the need for physical site visits. Virtual observational studies offer greater convenience for participants, leading to improved recruitment and retention rates. The ability to collect real-world data in real-time is also enhancing the validity and reliability of study findings.

In terms of industry, the virtual clinical trials market from the medical devices companies segment is estimated to rise at 7.2% CAGR through 2032. The advancements in remote monitoring technologies is enabling medical device companies to conduct trials more efficiently. Virtual trials reduce the logistical burden associated with traditional trials, ensuring faster and more cost-effective research. The regulatory support for virtual trial methodologies will further boost the segment growth.

Regionally, the Asia Pacific virtual clinical trials industry will showcase significant growth at 7.6% CAGR from 2024 to 2032. The increasing adoption of digital health technologies is facilitating remote data collection and patient engagement in the region. The rising demand for decentralized trial approaches is improving accessibility and diversity of participants. The rollout of supportive regulatory frameworks and guidelines are encouraging the adoption of virtual trial methodologies. Lately, the onset of the COVID-19 pandemic has also accelerated the shift towards virtual trials across APAC for ensuring continuity of research amid restrictions on in-person interactions.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Technological advancements in virtual clinical trials
  - 3.2.1.2 Rising penetration of technology in healthcare
  - 3.2.1.3 Development of novel medications for various diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory framework
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Study Design, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Interventional
5.3 Observational
5.4 Expanded access

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Fully virtual trials
6.3 Hybrid virtual trials

Chapter 7 Market Estimates and Forecast, By Phases, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Phase I
7.3 Phase II
7.4 Phase III
7.5 Phase IV

Chapter 8 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 CNS
8.3 Autoimmune/inflammation
8.4 Cardiovascular disease
8.5 Metabolic/endocrinology
8.6 Infectious disease
8.7 Oncology
8.8 Genitourinary
8.9 Ophthalmology
8.10 Other indications

Chapter 9 Market Estimates and Forecast, By Industry, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 Pharmaceutical and biotechnology companies
9.3 Contract research organizations (CROs)
9.4 Medical devices companies
9.5 Other industries

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa